Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications [12]
Approximately 25% of the weight lost on tirzepatide was lean mass rather than fat, and in semaglutide trials (STEP 1 DXA subset), that proportion may approach 40%
In addition, studies in which weight loss was greater during treatment than in the control group and studies in which lifestyle interventions were continued observed significant weight gain after drug discontinuation
But most studies are small, not well-designed and need to be interpreted with caution
This method delivers nutrients directly into the bloodstream
